Postchemotherapy residual masses in nonseminomatous germ cell tumor patients: 18F-FLT PET is unlikely to identify mature teratoma, but imaging of αvβ3 integrin expression could

Journal of Nuclear Medicine

Volumn 52, Issue 5, 2011, Pages 840-

  Joly, Florence ^b   Paciencia, Maria ^b   Bor, Catherine ^b   Aide, Nicolas ^a  

^a CENTRE FRANÇOIS BACLESSE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; CISPLATIN; COPPER 64; KI 67 ANTIGEN; RETINOIC ACID; TECHNETIUM 99M; VITRONECTIN RECEPTOR;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; DIAGNOSTIC VALUE; DRUG UPTAKE; EMBRYONIC STEM CELL; HUMAN; ISOTOPE LABELING; LETTER; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MINIMAL RESIDUAL DISEASE; NON SEMINOMATOUS GERMINOMA; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STEM CELL TRANSPLANTATION; TERATOCARCINOMA; TERATOMA; TUMOR NECROSIS;

DIDEOXYNUCLEOSIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHAVBETA3; NEOPLASM, RESIDUAL; NEOPLASMS, GERM CELL AND EMBRYONAL; POSITRON-EMISSION TOMOGRAPHY; TERATOMA;

EID: 79955771681     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.087171     Document Type: Letter

References (10)

1. 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? J Nucl Med. 2010;51:845-853.
2. De Wit R. Optimal management of retroperitoneal metastatic nonseminomatous testicular cancer: toward a better selection between scalpel and needle. J Clin Oncol. 2007;25:5550-5552.
3. Lutke Holzik MF, Hoekstra HJ, Mulder NH, Suurmeijer AJ, Sleijfer DT, Gietema JA. Non-germ cell malignancy in residual or recurrent mass after chemotherapy for nonseminomatous testicular germ cell tumor. Ann Surg Oncol. 2003;10:131-135. (Pubitemid 40485932)
4. Aide N, Comoz F, Sevin E. Enlarging residual mass after treatment of a nonseminomatous germ cell tumor: growing teratoma syndrome or cancer recurrence? J Clin Oncol. 2007;25:4494-4496.
5. 18F-FDG. J Nucl Med. 2003;44:1426-1431.
6. 18F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study. Eur J Nucl Med Mol Imaging. 2011;38:323-333.
7. Aide N, Poulain L, Briand M, et al. Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging. 2009;36:396-405.
8. Cao F, Li Z, Lee A, et al. Noninvasive de novo imaging of human embryonic stem cell-derived teratoma formation. Cancer Res. 2009;69:2709-2713.
9. Carver BS, Bianco FJ Jr, Shayegan B, et al. Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2006;176:100-103.
10. Sugawara Y, Zasadny K, Grossman HB, Francis IR, Clarke MF, Wahl RL. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology. 1999;211:249-255.